Navigation Links
Amylin Pharmaceuticals Reports Third Quarter Financial Results
Date:10/20/2009

2008. Revenues under collaborative agreements were $44.6 million for the nine months ended September 30, 2009, compared to $57.2 million for the same period in 2008. The decrease reflects lower cost-sharing payments from Lilly for development expenses for BYETTA and exenatide once weekly.

Selling, general and administrative expenses decreased to $259.7 million for the nine months ended September 30, 2009, from $309.0 million for the same period in 2008. The decrease primarily reflects lower sales force and business infrastructure expenses driven by the Company's reduced cost structure.

Research and development expenses decreased to $176.3 million for the nine months ended September 30, 2009, from $226.1 million for the same period in 2008. The decrease primarily reflects decreased development expenses for exenatide once weekly and the Company's obesity programs following recently completed clinical trials and efficiencies driven by the Company's reduced cost structure. Research and development expenses for the nine months ended September 30, 2008 included an $8.0 million license payment for drug delivery technology. Non-GAAP research and development expenses net of cost-sharing payments decreased to $134.9 million for the quarter ended September 30, 2009 compared to $172.1 million for the same period in 2008.

Collaborative profit sharing was $227.5 million for the nine months ended September 30, 2009, compared to $229.4 million for the same period in 2008.

Non-GAAP operating loss was $41.7 million for the nine months ended September 30, 2009, a 64% improvement over the $117.0 million loss for the same period in 2008. Net loss was $136.0 million, or $0.97 per share for the nine months ended September 30, 2009, compared to $216.7 million, or $1.58 per share, for the same period in 2008. Net loss for the nine months ended September 30, 2008 included a loss on impairment of investments of $14.9 million, or $0.11 p
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
3. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
4. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014  Seres Health, a clinical-stage therapeutics company ... human microbiome, announced today that Dr. David ... and Chief Scientific Officer, will be presenting at ... Chemotherapy (ICAAC). The presentation will highlight the scientific ... of bacterial spores derived from the human microbiome, ...
(Date:8/28/2014)... 2014  Stryker Orthopaedics, the Official Joint Replacement Products of ... of joint health to golf fans at the next stop ... Bank Championship. The company,s fan destination – "The Stryker Mobility ... 9" at the TPC Boston in Norton, MA ... At the Deutsche Bank Championship, Stryker will be ...
(Date:8/28/2014)... OAKS, Calif. , Aug. 28, 2014 ... submission of a Biologics License Application (BLA) to the ... approval for the treatment of high cholesterol. Evolocumab is ... convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces ... or "bad" cholesterol, from the blood. 1 ...
Breaking Medicine Technology:Seres Health to Present Clinical Findings at ICAAC 2014 Conference 2Stryker, Official Joint Replacement Products Of The PGA TOUR, Heads To Boston For The Deutsche Bank Championship 2Stryker, Official Joint Replacement Products Of The PGA TOUR, Heads To Boston For The Deutsche Bank Championship 3Stryker, Official Joint Replacement Products Of The PGA TOUR, Heads To Boston For The Deutsche Bank Championship 4Stryker, Official Joint Replacement Products Of The PGA TOUR, Heads To Boston For The Deutsche Bank Championship 5Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 2Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 3Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 4Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 5Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 6Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 7Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 8Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 9
... Oct. 31 2011 VolitionRX Limited (VNRX.OB) ("Volition" or the ... tests, publishes the following letter to its shareholders from Cameron ... speed at which our company has been growing and the ... would like to review the past year and look forward ...
... Japan, Oct. 31, 2011 Menicon Holdings BV and ... Thea, a France-based independent ophthalmic group, announced on October ... partner to market the SOLO-care (R) contact lens solutions ... and Canada. The agreement will enable Menicon ...
Cached Medicine Technology:VolitionRX Limited Issues Update Letter to Shareholders 2VolitionRX Limited Issues Update Letter to Shareholders 3VolitionRX Limited Issues Update Letter to Shareholders 4VolitionRX Limited Issues Update Letter to Shareholders 5Menicon to Market Eye Shelter's SOLO-care (R) Contact Lens Solution Range in Europe and Canada 2
(Date:8/28/2014)... BCC Research ( http://www.bccresearch.com ) reveals ... AND GLOBAL MARKETS , the global market for surgical ... Driven by the need for replacement of existing installations ... geographies, the market is expected to grow to $631.9 ... 8.5% from 2013 through 2018. , While revenue generation ...
(Date:8/28/2014)... Parker Waichman LLP, a national personal ... to ensure that the heroes of 9/11 are never ... WTC victims who developed 9/11-related cancer was reaffirmed by ... (GAO). According to a statement issued by 9/11 ... entitled “World Trade Center Health Program: Approach Used to ...
(Date:8/28/2014)... August 28, 2014 Clarity PSO ... been re-certified as a federal Patient Safety Organization (PSO) ... Agency for Healthcare Research and Quality (AHRQ). Clarity PSO ... expertise and services following the true intentions of the ... , ”We are proud and eager to continue our ...
(Date:8/28/2014)... CA (PRWEB) August 28, 2014 ... business sector recently launched a “Video” section located ... and general information on various cannabis companies in ... can find an assortment of news clips, interviews, ... and announcements. A portion of the videos can ...
(Date:8/28/2014)... PreDiabetes Centers, the nation’s top provider ... recipes to help clients and online readers send out ... Chef Han Ashley developed variations of Roasted Veggie ... , The PreDiabetes Centers Roasted Veggie Pizza recipe is ... and features a cheese substitute–ideal for people who are ...
Breaking Medicine News(10 mins):Health News:Global Market for Surgical Navigation Systems Expected to Reach $631.9 Million in 2018; ENT Systems Segment Leading With 10.4% CAGR 2Health News:Global Market for Surgical Navigation Systems Expected to Reach $631.9 Million in 2018; ENT Systems Segment Leading With 10.4% CAGR 3Health News:GAO Report Reaffirms Decision to Add Cancers to List of Illnesses Covered under the Zadroga Act, Parker Waichman LLP Comments 2Health News:GAO Report Reaffirms Decision to Add Cancers to List of Illnesses Covered under the Zadroga Act, Parker Waichman LLP Comments 3Health News:Clarity PSO Re-lists as a Patient Safety Organization and Continues to Advance Patient Safety 2Health News:Clarity PSO Re-lists as a Patient Safety Organization and Continues to Advance Patient Safety 3Health News:Emerging Cannabis Industry Website GreenRushReview.com Adds a Featured Video Section to Cover Marijuana Business Sector News 2Health News:Emerging Cannabis Industry Website GreenRushReview.com Adds a Featured Video Section to Cover Marijuana Business Sector News 3Health News:PreDiabetes Centers Concierge Chef Creates Tasty Grilled Veggie Pizza Recipes for Labor Day Party Menu 2Health News:PreDiabetes Centers Concierge Chef Creates Tasty Grilled Veggie Pizza Recipes for Labor Day Party Menu 3
... fall asleep swiftly if your hands and feet are warmer ... hot baths and// sleeping pills have all been put forward ... nothing beats the dilation of blood vessels in the hands ... ,Dr Kurt Krauchi and his team at the ...
... insomniacs would fare better if they kept the bed for ... A Canadian study found that taking sleeping pills worked in ... a long period. , Insomnia is defined as trouble ... early in the morning without being able to get back ...
... linked high levels of blood fats called triglycerides to ... physicians to pay closer attention to triglyceride levels.// More ... treatments to modify this stroke risk factor could further ... that drugs that lower blood fats can also prevent ...
... breast cancer patients feel better, but it won't help them ... their medical treatment lived an average// of 18 months longer. ... any longer than the 77 who got only medical treatmen. ... and emotional distress -- especially if the levels were high ...
... and other vascular diseases are the leading causes ... in depiction of stenotic, occlusive, aneurismal, inflammatory or ... (DSA) are used to depict vascular lesions with ... material.// It is the gold standard with a ...
... a common liver disease may be caused by the production ... to affect around one in four people in developed countries. ... currently untreatable, and one in ten sufferers go on to ... risk that cancer will develop in the organ.The damage caused ...
Cached Medicine News:Health News:Cure for sleepless nights 2Health News:Magnetic resonance angiography in clinical medicine 2
Electrohydraulic Lithotripsy Probe for AEH-2 & AEH-3...
Short double-horn bridge for insertion of instruments...
Only SurLok combines precise control, enhanced basket and grasper strength, and the added security of a unique wire-locking mechanism. You can feel the difference. The SurLok flat-wire and grasper ha...
... Tip 12 Inch , 20 inch,PVC, Length ... Available in 3,4,5 6Fr. These top quality ... flexible polymer material and have standard screw ... They are manufactured to the highest standards. ...
Medicine Products: